RIm13

Novel potent inhibitor of Proprotein convertase subtilisin/kexin 9 (PCSK9), targeting the PCSK9/LDLR protein-protein interaction

Mechanism of action

• RIm13 is described as a small-molecule drug whose main therapeutic target is the enzyme/protein PCSK9 (proprotein convertase subtilisin/kexin type 9). Synapse+1

• By inhibiting PCSK9, the compound aims to reduce the levels of low-density lipoprotein cholesterol (LDL-C). The rationale: PCSK9 normally binds to LDL receptors on liver cells and leads to their degradation, thus fewer LDL receptors means less clearance of LDL-C from the bloodstream. Inhibiting PCSK9 therefore increases LDL receptor availability and promotes LDL-C clearance. DOAJ+1

Development status & functional implications

• RIm13 is currently in the pre-clinical stage (i.e., not yet in approved clinical use). Synapse+1

• Its intended therapeutic indication is for hypercholesterolemia (elevated LDL cholesterol) via PCSK9 inhibition. Synapse

• Because it is still in early development, detailed functional data in humans (pharmacodynamics, pharmacokinetics, safety profile) are not publicly available.

• The general functionality (from the class of PCSK9 inhibitors) suggests that if successful, RIm13 might:

  • Lower LDL-C levels significantly (based on what is known from PCSK9 inhibitors generally).

  • Potentially reduce risk of cardiovascular events associated with high LDL-C (though this depends on clinical outcomes).

0°C (short term), -20°C (long term), desiccated